SIGA SIGA
SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.
Company profile
Ticker
SIGA
Exchange
Website
CEO
Phillip Louis Gomez
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SIGA PHARMACEUTICALS INC
SEC CIK
Corporate docs
IRS number
133864870
SIGA stock data
()
News
5 Value Stocks To Watch In The Healthcare Sector
24 May 21
SIGA Technologies Q1 EPS $(0.02) Up From $(0.11) YoY, Sales $4.80M Up From $2.62M YoY
6 May 21
Earnings Scheduled For May 6, 2021
6 May 21
SIGA Announces New Drug Application Filing With FDA For Intravenous Formulation Of TPOXX
4 May 21
A Look Into Healthcare Sector Value Stocks
29 Mar 21
Press releases
SIGA Reports Financial Results for Three Months Ended March 31, 2021
6 May 21
SIGA Technologies, Inc. to Host Earnings Call
6 May 21
SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX
4 May 21
SIGA Technologies to Host Business Update Call on May 6th, 2021 Following Release of First Quarter 2021 Financial Results
29 Apr 21
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
23 Mar 21
Calendar
6 May 21
13 Jun 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from SIGA earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 106.53M | 106.53M | 106.53M | 106.53M | 106.53M | 106.53M |
| Cash burn (monthly) | 3.79M | (positive/no burn) | 663.14K | (positive/no burn) | 1.6M | (positive/no burn) |
| Cash used (since last report) | 9.3M | n/a | 1.63M | n/a | 3.93M | n/a |
| Cash remaining | 97.23M | n/a | 104.9M | n/a | 102.59M | n/a |
| Runway (months of cash) | 25.7 | n/a | 158.2 | n/a | 64.0 | n/a |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Dec 20 | Julian Nemirovsky | Stock Option Common Stock, par value $.0001 per share | Grant | Aquire A | No | No | 7 | 25,000 | 175K | 25,000 |
| 27 Aug 20 | Antal James | Common Stock, Par Value $.0001 Per Share | Sell | Dispose S | No | No | 7.1 | 30,000 | 213K | 115,875 |
| 6 Aug 20 | Edward P. Taibi | Stock Option Common Stock, par value $.0001 per share | Grant | Aquire A | No | No | 6.52 | 25,000 | 163K | 25,000 |
| 6 Aug 20 | Edward P. Taibi | RSU Common Stock, par value $.0001 per share | Grant | Aquire A | No | No | 0 | 15,000 | 0 | 15,000 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
29.8% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 106 |
| Opened positions | 19 |
| Closed positions | 11 |
| Increased positions | 26 |
| Reduced positions | 37 |
13F shares |
Current |
|---|---|
| Total value | 195.79M |
| Total shares | 22.7M |
| Total puts | 19K |
| Total calls | 68K |
| Total put/call ratio | 0.3 |
Largest owners |
Shares | Value |
|---|---|---|
| BLK Blackrock | 4.69M | $30.48M |
| Vanguard | 2.58M | $16.79M |
| Esopus Creek Value Series Fund LP - Series A | 2.36M | $15.06M |
| Price Michael F | 1.21M | $7.84M |
| AltraVue Capital | 1.08M | $7.04M |
| STT State Street | 1.02M | $6.61M |
| Geode Capital Management | 874.52K | $5.68M |
| Renaissance Technologies | 767.01K | $4.99M |
| Hillsdale Investment Management | 647.1K | $4.21M |
| WFC Wells Fargo & Co. | 620.82K | $4.04M |
Financial report summary
?Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
Authorisation, broader, centralized, Code, complexity, covering, cowpox, decide, EMA, enable, EU, Europe, experience, expressed, firm, Food, Iceland, impose, infection, Liechtenstein, maintain, margin, Military, monkeypox, NDA, Norway, PHAC, proposal, Public, purpose, reduce, shelf, Simplifying, substantially, targeted, tecovirimat, timeline, unexpired, Vaccinia, variability, website
Removed:
accelerated, accreting, adjusted, affirmative, aforementioned, Aid, amortized, AMT, annum, assisting, assumed, August, Avenue, back, behalf, biological, capped, carried, Chairman, chemical, claim, closed, closing, Codification, commencement, comparable, comparison, Concession, conditioned, consulting, correction, dated, deemed, default, detailed, discontinued, discounted, discrepancy, discrete, Disposal, divide, Dr, elimination, emerging, employee, enacted, enhanced, Eric, event, excused, executing, Exit, expanded, expensed, expensing, expiry, extending, focused, footage, fully, furniture, geriatric, immaterial, improvement, individually, law, leasehold, legislation, LIBOR, limitation, local, located, Madison, maximum, meet, modification, nuclear, obligated, occurred, October, overlease, partially, pediatric, permit, permitting, physically, preceding, Priority, PRV, qualified, radiological, realization, recalled, reclassification, recoverability, reflected, refund, Relief, remote, removed, repaid, replacement, represented, requested, reserve, response, resulting, Rose, scheduled, site, situation, stated, sublease, subtenant, Suite, sum, taxable, technical, tendered, treasury, twelve, version, Voucher, warm, Web
Financial reports
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
4 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
5 Mar 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
5 Mar 19
Current reports
8-K
SIGA Reports Financial Results for Three Months Ended Summary Financial Results
6 May 21
8-K
SIGA Reports Financial Results for Three and Twelve
4 Mar 21
8-K
Entry into a Material Definitive Agreement
22 Jan 21
8-K
SIGA Announces Public Health Agency of Canada
13 Jan 21
8-K
Departure of Directors or Certain Officers
11 Dec 20
8-K
Results of Operations and Financial Condition
5 Nov 20
8-K
Departure of Directors or Certain Officers
2 Oct 20
8-K
Departure of Directors or Certain Officers
6 Aug 20
8-K
Results of Operations and Financial Condition
6 Aug 20
8-K
Departure of Directors or Certain Officers
26 Jun 20
Registration and prospectus
8-A12B
Registration of securities on exchange
19 Mar 18
S-8
Registration of securities for employees
4 Jun 17
424B3
Prospectus supplement
1 Nov 16
424B3
Prospectus supplement
20 Oct 16
S-1/A
IPO registration (amended)
18 Oct 16
S-1/A
2016 Q2
IPO registration (amended)
12 Oct 16
S-1/A
2016 Q2
IPO registration (amended)
19 Sep 16
S-1/A
2016 Q2
IPO registration (amended)
21 Aug 16
S-1
2015 Q1
IPO registration
5 Jun 16
25-NSE
Exchange delisting
20 May 15
Proxies
DEF 14A
Definitive proxy
27 Apr 21
DEFA14A
Additional proxy soliciting materials
1 Jun 20
DEF 14A
Definitive proxy
28 Apr 20
DEF 14A
Definitive proxy
29 Apr 19
DEF 14A
Definitive proxy
17 Apr 18
DEF 14A
Definitive proxy
16 Apr 17
DEF 14A
Definitive proxy
17 Apr 16
DEF 14A
Definitive proxy
13 Apr 15
DEF 14A
Definitive proxy
14 Apr 14
DEF 14A
Definitive proxy
15 Apr 13
Other
UPLOAD
Letter from SEC
19 Jul 20
CORRESP
Correspondence with SEC
25 Jun 20
UPLOAD
Letter from SEC
16 Jun 20
CT ORDER
Confidential treatment order
16 May 19
CT ORDER
Confidential treatment order
19 Nov 18
CT ORDER
Confidential treatment order
11 Oct 18
EFFECT
Notice of effectiveness
20 Oct 16
CORRESP
Correspondence with SEC
19 Oct 16
CORRESP
Correspondence with SEC
18 Oct 16
CORRESP
Correspondence with SEC
12 Oct 16
Ownership
SC 13D
SIGA / ESOPUS CREEK VALUE SERIES FUND LP - SERIES A ownership change
23 Feb 21
SC 13G/A
SIGA / BlackRock ownership change
31 Jan 21
SC 13G/A
SIGA / ESOPUS CREEK VALUE SERIES FUND LP - SERIES A ownership change
4 Jan 21
4
SIGA / Julian Nemirovsky ownership change
11 Dec 20
3
SIGA / Julian Nemirovsky ownership change
11 Dec 20
4
SIGA / James Antal ownership change
28 Aug 20
4
SIGA / Edward P. Taibi ownership change
7 Aug 20
3
SIGA / Edward P. Taibi ownership change
7 Aug 20
4
SIGA / Daniel J Luckshire ownership change
4 Aug 20
4
SIGA / Robin Elizabeth Abrams ownership change
4 Aug 20
Patents
APP
Utility
Polymorphic Forms of ST-246 and Methods of Preparation
13 May 21
Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
GRANT
Utility
Polymorphic forms of ST-246 and methods of preparation
2 Mar 21
Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
GRANT
Utility
ST-246 liquid formulations and methods
14 Dec 20
The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
GRANT
Utility
Rehydration of micronized tecovirimat monohydrate
20 Jul 20
Disclosed are methods for hydration of ST-246 particles comprising exposing said particles to moisture by conveying volumes of air containing moisture.
GRANT
Utility
Methods of preparing tecovirimat
25 May 20
Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
Reddit threads
Daily Discussion Thread - May 6th, 2021
6 May 21
Daily Discussion Thread - May 5th, 2021
5 May 21
Daily Discussion Thread - March 4th, 2021
4 Mar 21
Daily Discussion Thread - March 3rd, 2021
3 Mar 21
Daily Discussion Thread - March 2nd, 2021
2 Mar 21
Daily Discussion Thread - March 1st, 2021
1 Mar 21
Daily Discussion Thread - November 5th, 2020
5 Nov 20
Daily Discussion Thread - November 4th, 2020
4 Nov 20